Travere Therapeutics (NASDAQ:TVTX) EVP Peter Heerma Sells 102,190 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) EVP Peter Heerma sold 102,190 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $62.26, for a total transaction of $6,362,349.40. Following the completion of the sale, the executive vice president directly owned 117,066 shares of the company’s stock, valued at $7,288,529.16. The trade was a 46.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Heerma also recently made the following trade(s):

• On Thursday, September 17th, Peter Heerma sold 8,282 shares of Travere Therapeutics stock. The shares were sold at an average price of $65.07, for a total transaction of $538,909.74.
• On Wednesday, September 16th, Peter Heerma sold 172,717 shares of Travere Therapeutics stock. The stock was sold at an average price of $63.43, for a total transaction of $10,955,439.31.

Travere Therapeutics Stock Up 2.0%

Shares of Travere Therapeutics stock opened at $64.74 on Friday. Travere Therapeutics, Inc. has a twelve month low of $22.06 and a twelve month high of $68.73. The stock has a market cap of $6.10 billion, a price-to-earnings ratio of -140.74 and a beta of 1.05. The company has a current ratio of 4.05, a quick ratio of 3.99 and a debt-to-equity ratio of 24.58. The company has a fifty day moving average price of $61.63 and a 200 day moving average price of $48.50.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The firm’s revenue was up 48.2% compared to the same quarter last year. During the same period last year, the company posted $0.13 earnings per share. Equities research analysts forecast that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in Travere Therapeutics by 53.4% in the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after purchasing an additional 211 shares during the period. Corient Private Wealth LP increased its stake in Travere Therapeutics by 1.4% during the 2nd quarter. Corient Private Wealth LP now owns 48,125 shares of the company’s stock valued at $2,734,000 after buying an additional 648 shares during the period. ProShare Advisors LLC increased its stake in Travere Therapeutics by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 19,007 shares of the company’s stock valued at $726,000 after buying an additional 756 shares during the period. Allworth Financial LP acquired a new position in Travere Therapeutics during the 2nd quarter valued at about $47,000. Finally, Swiss National Bank raised its position in shares of Travere Therapeutics by 0.6% during the 1st quarter. Swiss National Bank now owns 168,100 shares of the company’s stock worth $4,994,000 after buying an additional 1,000 shares in the last quarter.

Analyst Upgrades and Downgrades

TVTX has been the topic of several recent research reports. Canaccord Genuity Group boosted their price target on Travere Therapeutics from $62.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Guggenheim increased their price objective on shares of Travere Therapeutics from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright lifted their price objective on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Wedbush boosted their target price on shares of Travere Therapeutics from $61.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Finally, Citigroup upped their target price on shares of Travere Therapeutics from $70.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.00.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.